 |
|
|
| |
HCV Guidelines Updated Feb 24 2016
|
| |
| |
What's New and Updates/Changes:
This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.
Updated recommendations reflecting this approval are provided in these sections:
Initial Treatment of HCV Infection
Retreatment of Persons in Whom Prior Therapy has Failed
Unique Patient Populations: Patients with Renal Impairment
Other updates reflecting recent data are provided in:
Unique Patient Populations: Patients with Decompensated Cirrhosis
Unique Patient Populations: Patients who Develop Recurrent HCV InfectionPost-Liver Transplantation
HCV Testing and Linkage to Care
Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:
Monitoring Patients who are Starting Hepatitis C Treatment, are on Treatment, or have Completed Therapy section.
Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:
Unique Patient Populations: Patients with HIV/HCV Coinfection
Unique Patient Populations: Patients who Develop Recurrent HCV InfectionPost-Liver Transplantation
Updated references have been provided throughout the Guidance.
Experts at the American Association for the Study for Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) have updatedHCVguidelines.org, a website developed to provide up-to-date guidance on the treatment of hepatitis C virus (HCV).
The updates reflect the approval of elbasvir/grazoprevir for treatment of HCV and guidance on testing for pre-existing resistance to some HCV medications.
Please see below for more information and let me know if you'd like to speak with a panel member.
Thanks,
Stephanie
Stephanie Goldina | On behalf of IDSA | 312.558.1770 ext. 142
HCV Guidance Website Updated to Reflect Latest Drug Developments
(February 24, 2016) HCVguidelines.org, a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the treatment of hepatitis C (HCV), has released updates on several sections of the website based on newly available therapies and data.
The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV. Based on the approval of this regimen, the website now also includes guidance on the role of testing for resistance to some HCV medications that may exist in patients prior to starting therapy.
While most sections of the guidance have been updated, the most significant changes have been made in the Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Treatment Has Failed sections as well as the Unique Populations sections, which include patients living with HIV, kidney disease, and severe liver disease including those with severe liver dysfunction and those who have had a liver transplant. Updated references have been provided throughout the guidance.
Visit www.HCVguidelines.org for updates regarding the release of this and other sections of the guidance.
|
| |
|
|
|
|
|
